PharmaCyte Biotech, Inc.
PMCB · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $13 | $15 | $16 | $21 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $5 | $4 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $3 | $0 | $0 |
| Total Curr. Assets | $19 | $22 | $17 | $21 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $2 | $2 | $2 | $2 |
| Long-Term Investments | $24 | $22 | $25 | $25 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $9 | $0 | $7 |
| Total NC Assets | $26 | $33 | $27 | $34 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $45 | $55 | $44 | $55 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $1 | $3 | $0 | $4 |
| Total Curr. Liab. | $1 | $3 | $1 | $5 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $2 | $7 |
| Total NC Liab. | $0 | $0 | $2 | $7 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $2 | $3 | $4 | $12 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$93 | -$85 | -$97 | -$94 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $137 | $137 | $137 | $137 |
| Total Equity | $44 | $52 | $40 | $43 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $45 | $55 | $44 | $55 |
| Net Debt | -$13 | -$15 | -$16 | -$21 |